ReNeuron Group plc Total Voting Rights (4683Y)

TIDMRENE

RNS Number : 4683Y

ReNeuron Group plc

02 January 2020

 
 2 January 2020   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

Total Voting Rights

At 31 December 2019, the Company had 31,833,770 ordinary shares in issue, each carrying one voting right. This follows the issue of 1,500 new shares arising from the exercise of options by staff, such shares having been admitted under the Company's existing block listing arrangement.

As the Company holds no ordinary shares in treasury, the figure of 31,833,770 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

ENDS

ENQUIRIES:

 
ReNeuron                                                [phone] 
Olav Hellebø, Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan (UK)                                           [phone] 
Mark Court, Tilly Abraham 
Argot Partners (US)                                       [phone] 
Stephanie Marks, Claudia Styslinger 
Stifel Nicolaus Europe Limited                          [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison 
 (NOMAD and Joint Broker) 
N+1 Singer                                              [phone] 
Aubrey Powell, James Moat, Mia Gardner (Joint Broker) 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

TVRUPUCCGUPUPUG

(END) Dow Jones Newswires

January 02, 2020 02:00 ET (07:00 GMT)